![conference banner](/images/conference-banner.jpeg)
Abstract
The number of patients with colorectal cancer, the third most frequently diagnosed malignancy in the world, has increased markedly over the past 20 years and will continue to increase in the future. Despite recent advances in chemotherapy, currently used anticancer molecules are unable to improve the prognosis of advanced or recurrent colorectal cancer, which remains incurable. The transport of classical drugs by nanoparticles has shown great promise in terms of improving drug distribution and bioavailability, increasing tissue half-life and concentrating anticancer molecules in the tumor mass, providing optimal drug delivery to tumor tissue, and minimizing drug toxicity, including those effects associated with pharmaceutical excipients. In addition, colon cancer targeting may be improved by incorporating ligands for tumor-specific surface receptors. Similarly, nanoparticles may interact with key drug-resistance molecules to prevent a reduction in intracellular drug levels drug. Recently published data have provided convincing pre-clinical evidence regarding the potential of active-targeted nanotherapeutics in colon cancer therapy, although, unfortunately, only a few of these therapies have been translated into early-phase clinical trials. As nanotechnology promises to be a new strategy for improving the prognosis of colon cancer patients, it would be very useful to analyze recent progress in this field of research. This review discusses the current status of nanoparticle-mediated cancer-drug delivery, the challenges restricting its application, and the potential implications of its use in colon cancer therapy.
Keywords: Colon cancer, chitosan, cytotoxic drugs, 5-fluorouracil, nanoparticles, drug resistance, P-glycoprotein.
Anti-Cancer Agents in Medicinal Chemistry
Title:Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Volume: 13 Issue: 8
Author(s): J. Prados, C. Melguizo, R. Ortiz, G. Perazzoli, L. Cabeza, P. J. Álvarez, F. Rodriguez-Serrano and A. Aranega
Affiliation:
Keywords: Colon cancer, chitosan, cytotoxic drugs, 5-fluorouracil, nanoparticles, drug resistance, P-glycoprotein.
Abstract: The number of patients with colorectal cancer, the third most frequently diagnosed malignancy in the world, has increased markedly over the past 20 years and will continue to increase in the future. Despite recent advances in chemotherapy, currently used anticancer molecules are unable to improve the prognosis of advanced or recurrent colorectal cancer, which remains incurable. The transport of classical drugs by nanoparticles has shown great promise in terms of improving drug distribution and bioavailability, increasing tissue half-life and concentrating anticancer molecules in the tumor mass, providing optimal drug delivery to tumor tissue, and minimizing drug toxicity, including those effects associated with pharmaceutical excipients. In addition, colon cancer targeting may be improved by incorporating ligands for tumor-specific surface receptors. Similarly, nanoparticles may interact with key drug-resistance molecules to prevent a reduction in intracellular drug levels drug. Recently published data have provided convincing pre-clinical evidence regarding the potential of active-targeted nanotherapeutics in colon cancer therapy, although, unfortunately, only a few of these therapies have been translated into early-phase clinical trials. As nanotechnology promises to be a new strategy for improving the prognosis of colon cancer patients, it would be very useful to analyze recent progress in this field of research. This review discusses the current status of nanoparticle-mediated cancer-drug delivery, the challenges restricting its application, and the potential implications of its use in colon cancer therapy.
Export Options
About this article
Cite this article as:
Prados J., Melguizo C., Ortiz R., Perazzoli G., Cabeza L., Álvarez J. P., Rodriguez-Serrano F. and Aranega A., Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/18715206113139990325
DOI https://dx.doi.org/10.2174/18715206113139990325 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amino Thiols, Detoxification and Oxidative Stress in Pre-Eclampsia and Other Disorders of Pregnancy
Current Pharmaceutical Design mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Translational Research and Standardization in Optical Imaging
Current Molecular Imaging (Discontinued) Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Genito-Urological Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Natural Excipients: Role in Nano Drug Delivery System
Current Nanomaterials GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Hypolipidemic, Antioxidant and Cardioprotective Effects of the Aqueous Extract from <i>Scorzanera Undulata</i> Tubers in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Cuproptosis Related Gene <i>DLD</i> Associated with Poor Prognosis and Malignant Biological Characteristics in Lung Adenocarcinoma
Current Cancer Drug Targets Mechanism of Action of Flavonoids as Anti-inflammatory Agents: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells
Mini-Reviews in Medicinal Chemistry Cancer-associated Cachexia, Reactive Oxygen Species and Nutrition Therapy
Current Medicinal Chemistry Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry Apoptotic and Anti-Angiogenic Effects of Benzimidazole Compounds: Relationship with Oxidative Stress Mediated Ischemia/Reperfusion Injury in Rat Hind Limb
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry